DDInter1293 DDInter1940
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO).[A258613,A258618,L45803] It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling pathway, vismodegib has anti-tumor activity in basal-cell carcinoma. The Hedgehog signaling pathway plays an important role in the development of organs and tissues during embryogenesis. Afterwards, it is silenced in all cells and tissues, except for hair, skin and stem cells. However, dysregulated or aberrant Hedgehog signaling has been associated with basal cell carcinoma pathogenesis.[A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma. In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803]
Nilotinib {u} may lead to a major life threatening interaction when taken with {v} Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolvaptan
Tolvaptan {u} (Compound) resembles {v} (Compound) Vismodegib
Nilotinib {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Vismodegib
Nilotinib {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Vismodegib
Nilotinib {u} may lead to a major life threatening interaction when taken with {v} Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolvaptan
Tolvaptan {u} (Compound) resembles {v} (Compound) Vismodegib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolvaptan
Tolvaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Nilotinib {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Nilotinib {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Sulfasalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Vismodegib
Nilotinib {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Nilotinib {u} (Compound) downregulates {v} (Gene) ITGAE
ITGAE {u} (Gene) is downregulated by {v} (Compound) Sulfasalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Vismodegib
Nilotinib may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib (Compound) resembles Vismodegib (Compound)
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan and Tolvaptan (Compound) resembles Vismodegib (Compound)
Nilotinib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Vismodegib (Compound)
Nilotinib (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Vismodegib (Compound)
Nilotinib may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan and Tolvaptan (Compound) resembles Vismodegib (Compound)
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan and Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Vismodegib (Compound)
Nilotinib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Nilotinib (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Sulfasalazine (Compound) and Sulfasalazine (Compound) resembles Vismodegib (Compound)
Nilotinib (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Nilotinib (Compound) downregulates ITGAE (Gene) and ITGAE (Gene) is downregulated by Sulfasalazine (Compound) and Sulfasalazine (Compound) resembles Vismodegib (Compound)